Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman - PubMed (original) (raw)

Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman

Akram Nakhaee et al. J Res Med Sci. 2013 May.

Abstract

Background: High prevalence of obesity and the importance of this issue as a risk factor for chronic diseases such as severe cardiovascular diseases, diabetes, and cancer necessitate the need for treatment. The aim of this study was the evaluation of acarbose effect on the weight loss in non diabetic overweight or obese patients in Kerman.

Materials and methods: A double blind randomized controlled clinical trial was performed on 66 patients with the body mass index (BMI) between 25 and 35 kg/m(2). Patients were divided in treatment and control groups using the randomization. The treatment group took 100 mg acarbose 3 times a day for 20 weeks in combination with the low calorie diet and exercise. Control group was given placebo, low calorie diet, and exercise. BMI was measured after 20 weeks. The analyses were carried out using t-test and repeated measured ANOVA.

Results: Patients in acarbose and placebo group had a non significant difference in BMI at baseline. Reducing in weight was considered in every month in both groups, but this reduction was higher in the treatment group. At the 5(th) month, the difference of BMI in the treatment group was significantly lower than the placebo group (2.31 ± 0.6 vs. 0.76 ± 0.6 kg/m(2), P < 0.001).

Conclusion: Acarbose, especially in combination with the low calorie diet and exercise, seems to lose weight effectively in obese and overweight patients in communities that have a high carbohydrate intake (like Persian diet).

Keywords: Acarbose; clinical trial; non-diabetics obese; weight loss.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1

Figure 1

The study fellow chart; enrollment and outcomes

Figure 2

Figure 2

Body mass index in each treatment in the treatment and placebo groups

Figure 3

Figure 3

Body mass index changes during intervals in the treatment and placebo group

Similar articles

Cited by

References

    1. Fact sheet: Obesity and overweight. [Internet] World Health Organization (WHO) 2013. Mar, Avalilable from: http://www.who.int/mediacentre/factsheets/fs311/en .
    1. Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence of metabolic syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions and their association with coronary heart disease in an elderly Iranian population. Ann Acad Med Singapore. 2009;38:142–9. - PubMed
    1. Krummel, Dabra A. Krause's Food, Nutrition and Diet Therapy. 11th ed. Philadelphia: WB Saunders; 2004. “Medical nutrition therapy in cardiovascular disease”; pp. 860–99.
    1. Kelishadi R, Ardalan G, Gheiratmand R, Gouya MM, Razaghi EM, Delavari A, et al. Association of physical activity and dietary behaviours in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bull World Health Organ. 2007;85:19–26. - PMC - PubMed
    1. Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications. 2003;17:179–85. - PubMed

LinkOut - more resources